Rhythm Pharmaceuticals announces ICD-10 diagnosis code for BBS

Rhythm Pharmaceuticals announced that a new International Classification of Diseases, Tenth Revision diagnosis code for Bardet-Biedl Syndrome was approved by the Centers for Disease Control and Prevention. The new code, Q87.83 Bardet-Biedl syndrome, takes effect Oct. 1, 2023. Prior to this code taking effect, health care providers were limited to reporting BBS diagnoses through ICD-10 code Q87.89, which is a generic code for congenital malformation syndromes not specific to BBS patients.